<DOC>
	<DOCNO>NCT00581555</DOCNO>
	<brief_summary>The purpose study evaluate use etanercept replacement therapy ciclosporin patient plaque psoriasis .</brief_summary>
	<brief_title>Evaluation Etanercept Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy</brief_title>
	<detailed_description>The purpose study evaluate efficacy safety etanercept replacement therapy ciclosporin patient moderate severe plaque psoriasis achieve adequate response ciclosporin .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Between age 18 70 year Active stable plaque psoriasis BSA≥10 PASI≥10 . Evidence skin condition psoriasis Psoralen plus psoralen + ultraviolet A ( PUVA ) , ciclosporin , acitretin , alefacept , anakinra , systemic antipsoriasis therapy diseasemodifying antirheumatic drug ( DMARD ) 28 day screen ultraviolet B ( UVB ) therapy , topical steroid , topical Vitamin A D analog preparation , anthralin Prior exposure TNFinhibitor . Prior exposure efalizumab Corticosteroid dose prednisone &gt; 10 mg/day Serious infection Receipt live vaccine Abnormal hematology chemistry Body mass index ( BMI ) &gt; 38 Pregnancy Breastfeeding Significant concurrent medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>